Table 2.
Hazard ratio for overall and disease specific death in HNSCC-DM patients by univariate Cox-proportional hazard model analysis.
| Characteristic | Overall death |
Disease specific death |
||
|---|---|---|---|---|
| HR1 (95 %CI2) | p-value | HR1 (95 %CI2) | p-value | |
|
| ||||
| Age | ||||
| <=62 | Reference | Reference | ||
| >62 | 1.07 (0.893–1.29) | 0.448 | 0.909 (0.733–1.13) | 0.382 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.07 (0.854–1.35) | 0.546 | 0.937 (0.711–1.23) | 0.644 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.06 (0.804–1.39) | 0.691 | 1.01 (0.731–1.4) | 0.938 |
| Others | 0.764 (0.548–1.06) | 0.111 | 0.945 (0.664–1.35) | 0.756 |
| Primary site | ||||
| Hypopharynx | Reference | Reference | ||
| Nasopharynx | 0.471 (0.324–0.684) | < 0.001 | 0.604 (0.393–0.93) | 0.022 |
| Oropharynx | 0.622 (0.474–0.816) | < 0.001 | 0.705 (0.507–0.982) | 0.038 |
| Grade | ||||
| I, II | Reference | Reference | ||
| III, IV | 0.737 (0.589–0.923) | < 0.001 | 0.782 (0.602–1.02) | 0.065 |
| Unknown | 0.819 (0.644–1.04) | 0.104 | 0.85 (0.642–1.12) | 0.255 |
| HPV status | ||||
| HPV Negative | Reference | Reference | ||
| HPV Positive | 0.594 (0.492–0.717) | < 0.001 | 0.698 (0.563–0.866) | 0.001 |
| T stage | ||||
| T1, T2 | Reference | Reference | ||
| T3, T4 | 1.37 (1.11–1.71) | 0.004 | 1.36 (1.05–1.75) | 0.019 |
| Unknown | 1.2 (0.927–1.56) | 0.166 | 1.27 (0.944–1.71) | 0.114 |
| N stage | ||||
| N1, N2 | Reference | Reference | ||
| N2, N3 | 1.13 (0.905–1.4) | 0.285 | 1.42 (1.09–1.85) | 0.0105 |
| Unknown | 1.02 (0.719–1.43) | 0.931 | 1.09 (0.716–1.66) | 0.69 |
| Insurance | ||||
| Insured | Reference | Reference | ||
| Medicaid | 1.18 (0.946–1.46) | 0.144 | 1.2 (0.936–1.55) | 0.148 |
| Uninsured | 1.39 (0.947–2.03) | 0.0931 | 1.57 (1.03–2.39) | 0.036 |
| Unknown | 0.89 (0.474–1.67) | 0.717 | 1.1 (0.564–2.14) | 0.783 |
| Marriage | ||||
| Married | Reference | Reference | ||
| Separated | 1.63 (1.3–2.05) | < 0.001 | 1.32 (1 –1.73) | 0.048 |
| Unmarried | 1.41 (1.12–1.78) | 0.004 | 1.45 (1.12–1.88) | 0.004 |
| Unknown | 1.14 (0.764–1.71) | 0.513 | 1.04 (0.644–1.68) | 0.875 |
| Treatment | ||||
| Single treatment | Reference | Reference | ||
| Comprehensive Therapya | 0.593 (0.48–0.733) | < 0.001 | 0.642 (0.501–0.823) | < 0.001 |
| No/Unknown | 3.35 (2.56–4.4) | < 0.001 | 3.58 (2.61–4.89) | < 0.001 |
| Bone | ||||
| Yes | Reference | Reference | ||
| No | 0.642 (0.527–0.782) | < 0.001 | 0.552 (0.442–0.69) | < 0.001 |
| Lung | ||||
| Yes | Reference | Reference | ||
| No | 0.761 (0.632–0.917) | 0.004 | 0.702 (0.566–0.871) | 0.001 |
| Liver | ||||
| Yes | Reference | Reference | ||
| No | 0.796 (0.626–1.01) | 0.062 | 0.702 (0.538–0.918) | 0.01 |
| Brain | ||||
| Yes | Reference | Reference | ||
| No | 0.559 (0.37–0.845) | 0.006 | 0.494 (0.314–0.777) | 0.002 |
| Number of metastatic sites | ||||
| 1 | Reference | Reference | ||
| >=2 | 0.91 (0.685–1.21) | 0.517 | 0.862 (0.63–1.18) | 0.355 |
1
HR = Hazard Ratio;
2
CI = Confidence Interval
a
two or more than two treatments were given to patients such as chemotherapy plus radiotherapy